1.00 / AMA PRA Category 1 CreditTM 1.00 / Pharmacist Contact Hours (0.10 CEUs)
Purdue University College of Pharmacy
Supported by educational grants from Sanofi US, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
Type 2 diabetes (T2D) is a chronic, highly prevalent disease. Despite the availability of many treatment options, including new insulin formulations that have the potential to simplify treatment regimens, improve treatment adherence, and provide clinical benefit, patients often have poor glycemic control. This activity will examine the role of insulin therapy in the management of T2D.
Endocrinologists, primary care/internal medicine physicians, and other clinicians including pharmacists, nurse practitioners (NPs), physician assistants (PAs), nurses, and diabetes educators involved in the management of patients with T2D.
Upon completion of this educational activity, participants should be able to:
Initiate and adjust insulin therapy in appropriate patients with T2D who have not achieved glycemic control on non-insulin therapy.
Develop strategies to overcome patient-related adherence barriers to the use of insulin in patients with T2D.
Summarize the current evidence-based practice guidelines for glycemic control in patients with T2D.
Describe the benefits and risks of currently approved insulin therapies.
Conflict Of Interest Disclosure Policy
The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Faculty Presenter Carol H. Wysham, MD, FACP, FACE Clinical Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes and Endocrinology Spokane, WA
Dr. Wysham has disclosed the following: Consultant: Astra Zeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, and Sanofi Speaker Bureau: Astra Zeneca, Boehringer Ingelheim, Insulet, Janssen, Novo Nordisk, and Sanofi Advisory Board: Abbott, Janssen, Novo Nordisk, and Sanofi
Additional Content Development Faculty John L. Leahy, MD Co-Chief, Division of Endocrinology, Diabetes, and Metabolism Professor of Medicine University of Vermont College of Medicine Director, Vermont Regional Diabetes Center Burlington, VT
Dr. Leahy has disclosed the following: Advisory Board: Novo Nordisk, Merck, Sanofi, Janssen, Valeritas
Serena Cardillo, MD Associate Professor of Clinical Medicine Division of Endocrinology, Diabetes, and Metabolism Perelman School of Medicine at the University of Pennsylvania Perelman Center for Advanced Medicine Philadelphia, PA
Dr. Cardillo has no relevant affiliations or financial relationships with a commercial interest to disclose.
Carrie M. Burns, MD Associate Professor of Clinical Medicine Division of Endocrinology, Diabetes, and Metabolism Perelman School of Medicine at the University of Pennsylvania Perelman Center for Advanced Medicine Philadelphia, PA
Dr. Burns has no relevant affiliations or financial relationships with a commercial interest to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Pharmacists
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.
Universal Activity Number (UAN): 0018-9999-18-113-H01-P; 1.00 contact hour (0.10 CEU).
Disclosure of Unlabeled Use
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.